{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:14:58Z","timestamp":1790716498567,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172921"],"award-info":[{"award-number":["82172921"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022957","name":"Double Thousand Plan of Jiangxi Province","doi-asserted-by":"publisher","award":["jxsq2019201027"],"award-info":[{"award-number":["jxsq2019201027"]}],"id":[{"id":"10.13039\/100022957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37544","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T17:41:15Z","timestamp":1725644475000},"page":"e37544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database"],"prefix":"10.1016","volume":"10","author":[{"given":"Fuchun","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhuo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Situ","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-3061","authenticated-orcid":false,"given":"Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4188-5329","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e37544_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.heliyon.2024.e37544_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-017-2115-4","article-title":"Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature","volume":"36","author":"Mari","year":"2018","journal-title":"World J. Urol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib3","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.heliyon.2024.e37544_bib4","doi-asserted-by":"crossref","first-page":"v118","DOI":"10.1093\/annonc\/mdj965","article-title":"Long-term survival results of a randomized trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer","volume":"17","author":"Roberts","year":"2006","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.heliyon.2024.e37544_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2019.1671190","article-title":"Erdafitinib for the treatment of urothelial cancer","volume":"19","author":"Marandino","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.heliyon.2024.e37544_bib6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e37544_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.euf.2018.02.013","article-title":"Prognostic effect of FGFR mutations or gene fusions in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: results from a large, single-institution cohort","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.heliyon.2024.e37544_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11934-015-0566-y","article-title":"Prognostic genetic signatures in upper tract urothelial carcinoma","volume":"17","author":"Li","year":"2016","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.heliyon.2024.e37544_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1535-7163.MCT-12-1150","article-title":"Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer","volume":"12","author":"Gust","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.heliyon.2024.e37544_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.heliyon.2024.e37544_bib11","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.heliyon.2024.e37544_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13555-019-00341-2","article-title":"Injection site reactions in the federal adverse event reporting system (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis","volume":"10","author":"Grace","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.heliyon.2024.e37544_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA queries: their role in signal detection","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e37544_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e37544_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH)","volume":"37","author":"Baber","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e37544_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e37544_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Statistician"},{"key":"10.1016\/j.heliyon.2024.e37544_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2457","article-title":"Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation","volume":"9","author":"Takai","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib21","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e37544_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","article-title":"A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth","volume":"375","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2024.e37544_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e37544_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2009.09076.x","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.heliyon.2024.e37544_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12894-024-01488-7","article-title":"Establishment and validation of a nomogram for predicting overall survival of upper-tract urothelial carcinoma with bone metastasis: a population-based study","volume":"24","author":"Hu","year":"2024","journal-title":"BMC Urol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/09546634.2015.1115818","article-title":"Keratosis lichenoides chronica: case-based review of treatment options","volume":"27","author":"Pistoni","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.heliyon.2024.e37544_bib28","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","article-title":"Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma","volume":"47","author":"Marques-Piubelli","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102574","article-title":"Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer","volume":"90","author":"Reike","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.heliyon.2024.e37544_bib30","first-page":"437","article-title":"Bevacizumab-induced bowel perforation","volume":"111","author":"Sliesoraitis","year":"2011","journal-title":"J. Am. Osteopath. Assoc."},{"key":"10.1016\/j.heliyon.2024.e37544_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin\u2013related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"10.1016\/j.heliyon.2024.e37544_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MOG.0000000000000813","article-title":"Drug-induced bile duct injury: new agents, new mechanisms","volume":"38","author":"Scoazec","year":"2022","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2147\/NDT.S83989","article-title":"Rare and very rare adverse effects of clozapine","volume":"11","author":"De Fazio","year":"2015","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.heliyon.2024.e37544_bib34","article-title":"A progressive spontaneous cervical compression fracture over years following long-term corticosteroid use","volume":"15","author":"Maki","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e37544_bib35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/nau.24341","article-title":"What urologists need to know about ketamine-induced uropathy: a systematic review","volume":"39","author":"Castellani","year":"2020","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.heliyon.2024.e37544_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.20452\/pamw.2715","article-title":"New insight into the mechanisms of gastroduodenal injury induced by nonsteroidal anti-inflammatory drugs: practical implications","volume":"125","author":"Kwiecie\u0144","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.heliyon.2024.e37544_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37544_bib38","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.apsb.2021.05.028","article-title":"Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury via mitochondrial or other mechanisms","volume":"11","author":"Rana","year":"2021","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402413575X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402413575X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:28:36Z","timestamp":1790713716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402413575X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S240584402413575X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37544","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37544"}}